- Mecillinam USP/EP/BP
-
- $1.10 / 1g
-
2021-06-25
- CAS:32887-01-7
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
- AMdinocillin
-
- $1.00 / 1KG
-
2020-05-10
- CAS: 32887-01-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20T
- mecillinam
-
- $1.00 / 1KG
-
2020-01-10
- CAS:32887-01-7
- Min. Order: 1KG
- Purity: 98% HPLC
- Supply Ability: 10 tons/month
|
| | Mecillinam Basic information |
| | Mecillinam Chemical Properties |
| Melting point | 156°C | | Boiling point | 551℃ | | alpha | D20 +285° (c = 1 in 0.1N HCl) | | density | 1.44±0.1 g/cm3(Predicted) | | Fp | >110°(230°F) | | storage temp. | Sealed in dry,2-8°C | | solubility | Methanol (Slightly), Water (Slightly) | | pka | pKa 3.40 (Uncertain) | | color | White to Off-White | | Water Solubility | Soluble in water at approximately 1mg/ml | | CAS DataBase Reference | 32887-01-7(CAS DataBase Reference) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 2 | | RTECS | XI0185000 |
| | Mecillinam Usage And Synthesis |
| Chemical Properties | White Solid | | Originator | Selexidin,Leo,UK,1979 | | Uses | Effective against Gram-negative bacteria | | Uses | Active antibacterial against gram-negative bacteria | | Uses | Mecillinam (amidinocillin) is a penicillin nucleus (6 APA) derivative, active in vitro against most aerobic and anaerobic Gram-negative bacilli, including E. coli and B. fraglis, but not active against Staphylococcus aureus, Enterococcus, or Pseudomonas. Mecillinam is synergistic with other beta-lactam drugs and therefore can be used in combination to treat severe Gram-negative infections. Although its in vitro efficacy is convincing, there are not enough clinical trials to support its use for intra-abdominal infections. | | Definition | ChEBI: Mecillinam is a penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria. It has a role as an antibacterial drug and an antiinfective agent. | | Manufacturing Process | The starting material N-formylhexamethyleneimine was prepared from hexamethyleneimine and chloral.
12.7 g of N-formylhexamethyleneimine were dissolved in 250 ml of dry ether.
While stirring and cooling, 8.5 ml of oxalyl chloride in 50 ml of dry ether were
added dropwise, whereafter the mixture was stirred overnight at room
temperature. The precipitated amide chloride was filtered off and washed with
dry ether, and was placed in an exsiccator.
A solution of the amide chloride (4.6 g) in dry, alcohol-free chloroform (20 ml)
was added slowly to a solution of trimethylsilyl 6-amino-penicillanate (7.2 g)
and triethylamine (3.5 ml) in dry, alcohol-free chloroform (50 ml) with stirring
and cooling to -70°C. The temperature was raised to 0°C during 1.5 hours.
The solution was evaporated to dryness in vacuo and the residue was
triturated with dry ether (200 ml). The precipitate was filtered off and washed
with dry ether. The filtrate was diluted with ether (200 ml). 2-Butanol (2.8 ml)
was added dropwise with stirring and cooling to 0°C. The stirring was
continued for 1/4 hour at 0°C, whereupon the precipitate was filtered off,
washed with ether and dried. It was a white, amorphous powder, soluble in
water. | | Brand name | Coactin (Roche). | | Therapeutic Function | Antibacterial | | Antimicrobial activity | The antibacterial spectrum differs greatly from that of the
aminopenicillins in that the compound displays high activity
against many Gram-negative bacteria but limited activity
against Gram-positive organisms.
Mecillinam is active against many Enterobacteriaceae due to
its selective binding to PBP 2, although the susceptibility of
Proteus and Providencia spp. is variable. H. influenzae is less susceptible
than enteric bacilli, and Acinetobacter spp., B. fragilis
and Ps. aeruginosa are resistant.
It is readily inactivated by many β-lactamases, although it
is more stable than ampicillin. | | Acquired resistance | Intrinsic resistance in susceptible species of enterobacteria
is uncommon and many ampicillin-resistant strains are susceptible.
Bacteria that are resistant to both ampicillin and
mecillinam are usually those producing large amounts of
β-lactamase, most commonly plasmid-mediated enzymes. | | Pharmacokinetics | Oral absorption (pivmecillinam): c. 75%
Cmax 200 mg intravenous infusion: 12 mg/L end infusion
200 mg intramuscular: c. 6 mg/L after 45 min
400 mg oral (pivmecillinam): 2–5 mg/L after c. 1 h
Plasma half-life: 50 min
Volume of distribution: 0.2–0.4 L/kg
Plasma protein binding: 5–10%
Absorption
Oral absorption is very poor, with conventional doses producing plasma levels of <1 mg/L and recovery of only about 5% in the urine. A 400 mg dose of the pivaloyl ester is equivalent to 273 mg mecillinam. It is relatively well absorbed and rapidly liberates the parent compound. Metabolism and excretion
The amidino side chain undergoes spontaneous aqueous hydrolysis to the N-formyl derivative, which retains some antibacterial activity. Hydrolysis of the β-lactam ring also occurs.
Approximately 60% is excreted unchanged in the urine in the first 6 h, achieving concentrations exceeding 1 g/L. The concentration in bile can reach 40 or 50 mg/L in patients with normally functioning gallbladders treated with 800 mg intramuscularly. | | Clinical Use | Urinary tract infection (pivmecillinam)
Other infections with susceptible Gram-negative bacilli (usually in
combination with other agents) | | Side effects | It is generally well tolerated, and serious anaphylactic responses
are said to be rare. Nausea and vomiting, which may be persistent,
occur with diarrhea in some patients treated with
pivmecillinam. |
| | Mecillinam Preparation Products And Raw materials |
|